long intergenic non-protein coding RNA 2257Genealiases: []
Q-omics provides the consensus-scored LINC02257 profile across patient tissues and cancer cell-line models. LINC02257 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC02257 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, LINC02257 RNA expression shows 14,044 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight COAD, and BRCA as cancer lineages where LINC02257 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02257 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02257 survival associations across molecular data types. LINC02257 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02257 RNA expression–survival associations across cancer types. High LINC02257 expression shows unfavorable associations in COAD, KIRC, PAAD, KIRP, OV and UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC02257 RNA expression.
This table summarizes LINC02257 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02257. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02257 shows higher tumor expression in COAD, BLCA, THCA, LUAD, BRCA and STAD. The COAD box plot shows higher LINC02257 RNA expression in tumor versus normal tissue (log2 FC = +0.620, t-test p < 0.001).
This table shows molecular features associated with LINC02257 in patient tissues and cancer cell lines. In patient samples, LINC02257 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
